The Technical Analyst
Galera Therapeutics Inc [GRTX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Galera Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-1.08% $0.184
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 10.01 mill |
| EPS: | -1.330 |
| P/E: | -0.140 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 54.39 mill |
| Avg Daily Volume: | 1.993 mill |
| RATING 2024-04-19 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Buy | |
| Return On Asset: | Sell | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.140 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.02x |
| Company: PE -0.140 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.153 - 0.215 ( +/- 16.85%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-12-31 | Altamont Pharmaceutical Holdings, Llc | Buy | 0 | |
| 2024-02-08 | Schneid Yair | Buy | 150 000 | Common Stock |
| 2024-02-07 | Schneid Yair | Buy | 150 000 | Common Stock |
| 2024-02-07 | Schneid Yair | Buy | 25 000 | Common Stock |
| 2024-02-06 | Schneid Yair | Buy | 25 000 | Common Stock |
| INSIDER POWER |
|---|
| 99.55 |
| Last 95 transactions |
| Buy: 5 055 072 | Sell: 1 341 015 |
Forecast:
16:00 - $0.185
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.185
Forecast 2: 16:00 - $0.185
Forecast 3: 16:00 - $0.185
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.184 (-1.08% ) |
| Volume | 0.801 mill |
| Avg. Vol. | 1.993 mill |
| % of Avg. Vol | 40.21 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For GRTX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
GRTX
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Latest Press Releases
2024-03-28 07:00:00 - Press Release
Galera Reports Fourth Quarter And Full Year 2023 Financial Results And Recent Corporate Updates
Company continues to evaluate strategic options to maximize shareholder value company continues to evaluate strategic options to maximize shareholder value
2023-11-14 07:00:00 - Press Release
Galera Reports Third Quarter 2023 Financial Results And Recent Corporate Updates
Fda confirms need for new trial for avasopasem; greco trials with rucosopasem to be discontinued company evaluating potential strategic options to optimize shareholder value malvern, pa., nov. 14, 2023 (globe newswire) -- galera therapeutics, inc. (nasdaq: grtx), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the third quarter ended september 30, 2023 and provided recent corporate updates.
2023-10-31 07:00:00 - Press Release
Galera Announces Receipt Of Type A Meeting Minutes And Strategic Update
Fda confirms need for new trial for avasopasem for severe oral mucositis (som) greco-2 trial did not pass futility analysis; company will discontinue both greco trials company reviewing potential strategic alternatives to maximize shareholder value malvern, pa., oct. 31, 2023 (globe newswire) -- galera therapeutics, inc. (nasdaq: grtx), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that it has received official meeting minutes from the type a meeting with the united states food and drug administration (fda) held september 28, 2023 in which the fda reiterated the need for an additional phase 3 trial of avasopasem manganese (avasopasem) for radiotherapy-induced som.
2023-09-18 07:00:00 - Press Release
Galera Schedules Type A Meeting With Fda To Discuss Next Steps For Avasopasem
Malvern, pa., sept. 18, 2023 (globe newswire) -- galera therapeutics, inc. (nasdaq: grtx), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that a type a meeting has been scheduled for september 28, 2023 with the u.s. food and drug administration (fda) regarding the complete response letter (crl) received for the company's new drug application (nda) for avasopasem manganese (avasopasem). the fda is expected to issue written meeting minutes approximately 30 days following the meeting.
2023-08-14 07:00:00 - Press Release
Galera Reports Second Quarter 2023 Financial Results And Recent Corporate Updates
Company received complete response letter from fda for avasopasem and intends to request type a meeting with fda to discuss potential next steps
Latest News
2023-09-06 07:36:51 - Benzinga
Top 5 Health Care Stocks That May Explode In Q3 - BioVie (NASDAQ:BIVI), Galera Therapeutics (NASDAQ:GRTX)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
2023-08-14 08:39:08 - Zacks Investment Research
3 Biotech Stocks Poised to Beat Q2 Earnings Estimates
We look at a few biotech companies, LEGN, KOD, GRTX, which are poised to beat second-quarter earnings estimates.
2023-08-10 13:04:50 - Proactive Investors
Galera Therapeutics shares plummet after FDA rejects drug for cancer treatment side effect
Galera Therapeutics shares plunged by almost 85% after the clinical-stage biopharmaceutical company revealed its New Drug Application for its investigational therapeutic avasopasem manganese (avasopasem) for radiotherapy-induced severe oral mucositis in patients with head and neck cancer undergoing standard-of-care treatment was not approved by the Food and Drug Administration (FDA). The company said that the FDA had informed it that the data from its Phase 3 ROMAN trial and supporting data from its GT-201 trial were “not sufficiently persuasive to establish substantial evidence of avasopasem's effectiveness and safety for reducing severe oral mucositis in patients with head and neck cancer.
2023-08-10 08:43:28 - InvestorPlace
Why Is Galera Therapeutics (GRTX) Stock Down 83% Today?
Galera Therapeutics (NASDAQ: GRTX ) stock is falling hard on Thursday following a drug rejection by the FDA! In a Complete Response Letter ( CRL ), the FDA rejected the company's New Drug Application (NDA) for avasopasem manganese.
2023-08-09 19:00:48 - Reuters
Galera shares tank after US FDA declines to approve inflammation disease drug
Galera Therapeutics Inc said the U.S. health regulator declined to approve its drug to treat radiotherapy-induced severe mouth inflammation in patients with advanced head and neck cancer undergoing standard-of-care treatment.
2023-04-26 10:00:00 - GlobeNewsWire
Galera to Present One-Year Reductions in Cisplatin-Related Chronic Kidney Disease Data from ROMAN Trial at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
MALVERN, Pa., April 26, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that a prespecified analysis from the Phase 3 ROMAN trial detailing one-year reductions in cisplatin-related chronic kidney disease in patients with head and neck cancer treated with avasopasem will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, 2023, in Chicago, IL.
2023-04-24 18:33:13 - Seeking Alpha
Galera Therapeutics: A Possible Solution To Severe Oral Mucositis In Head And Neck Cancer Patients
Galera Therapeutics: A Possible Solution To Severe Oral Mucositis In Head And Neck Cancer Patients.
2023-02-21 22:24:43 - 24/7 Wall Street
Piper Sandler Initiates Coverage of Galera Therapeutics With Overweight Recommendation
On February 21, 2023, Piper Sandler initiated coverage of Galera Therapeutics with a Overweight recommendation.
2022-11-22 07:00:00 - GlobeNewsWire
Galera to Present at Piper Sandler Annual Healthcare Conference
MALVERN, Pa., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will present at the Piper Sandler 34th Annual Healthcare Conference on Tuesday, November 29, 2022 at 11:10 a.m. E.T.
2022-09-26 07:00:00 - GlobeNewsWire
Galera to Present at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting
MALVERN, Pa., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that tumor outcomes data from its Phase 3 ROMAN trial of avasopasem for severe oral mucositis (SOM) and final data from its Phase 2 AESOP trial of avasopasem for chemoradiotherapy-induced esophagitis will be highlighted in two presentations at the upcoming 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting, taking place October 23-26, 2022 in San Antonio, Texas. Additionally, poster presentations will highlight the Phase 2 EUSOM trial of avasopasem for SOM in Europe and the ongoing GRECO-1 trial of rucosopasem for non-small cell lung cancer.